Continuous vs Intermittent β-Lactam Antibiotic Infusions for Sepsis—Reply
In Reply Dr Han and colleagues ask why pharmacokinetic considerations, antibiotic resistance details, and outcome measures other than sepsis survival did not feature more prominently in the BLING III trial.1
Authors
- Joel M. Dulhunty (ORCID: https://orcid.org/0000-0002-4524-0548)
- Jason A. Roberts (ORCID: https://orcid.org/0000-0001-6218-435X)
- Jeffrey Lipman (ORCID: https://orcid.org/0000-0002-5965-9876)
Institutions
- The University of Queensland (AU)
- Royal Brisbane and Women's Hospital (AU)
- Redcliffe Hospital (AU)
Publication Details
- Journal
- JAMA
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1001/jama.2024.23275
- Citations
- 3
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 1.34